Evidence map›Paper›PMID 28983453›Full record

ArticleCurrent pharmacology reports2017

Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites.

Zidong Donna Fu, Julia Yue Cui

Abstract read
In one paragraph

Article in Current pharmacology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 54 citations in OpenAlex.

  1. Effects of DifferentMicroorganisms · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Gut Microbiome Critically Impacts PCB-induced Changes in Metabolic Fingerprints and the Hepatic Transcriptome in Mice.Toxicological sciences : an official journal of the Society of Toxicology · 2020
    Article
  15. Bioavailability Based on the Gut Microbiota: a New Perspective.Microbiology and molecular biology reviews : MMBR · 2020
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Zidong Donna FuDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle WA 98105.
Julia Yue CuiDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle WA 98105.
Theodore Roosevelt High School · USUniversity of Washington · US

Funding

XENOBIOTIC BIOTRANSFORMATION AND DISPOSITIONP30ES007033 · NIEHS · UNIVERSITY OF WASHINGTON · PI Sheela Sathyanarayana · 1995 to 2026
$42.5M
Developmental Regulation of Drug Processing GenesR01ES019487 · NIEHS · UNIVERSITY OF WASHINGTON · PI CUI, JULIA YUE, LU, HONG · 2010 to 2014
$3.0M
Epigenetic Regulation of Drug Metabolism by Developmental Exposure to PBDEsR01ES025708 · NIEHS · UNIVERSITY OF WASHINGTON · PI CUI, JULIA YUE · 2015 to 2019
$1.7M
Developmental Regulation of Drug Metabolism by Targeting the Gut MicrobiomeR01GM111381 · NIGMS · UNIVERSITY OF WASHINGTON · PI CUI, JULIA YUE · 2014 to 2018
$1.5M
NIEHS NIH HHS P30 ES007033NIEHS NIH HHS R01 ES019487NIEHS NIH HHS R01 ES025708NIGMS NIH HHS R01 GM111381
6 · The paper itself

Abstract

Recent technological advancements including metagenomics sequencing and metabolomics have allowed the discovery of critical functions of gut microbiota in obesity, malnutrition, neurological disorders, asthma, and xenobiotic metabolism. Classification of the human gut microbiome into distinct "enterotypes" has been proposed to serve as a new paradigm for understanding the interplay between microbial variation and human disease phenotypes, as many organs are affected by gut microbiota modifications during the pathogenesis of diseases. Gut microbiota remotely interacts with liver and other metabolic organs of the host through various microbial metabolites that are absorbed into the systemic circulation. PURPOSE OF REVIEW: The present review summarizes recent literature regarding the importance of gut microbiota in modulating the physiological and pathological responses of various host organs, and describes the functions of the known microbial metabolites that are involved in this remote sensing process, with a primary focus on the gut microbiota-liver axis. RECENT

findingsUnder physiological conditions, gut microbiota modulates the hepatic transcriptome, proteome, and metabolome, most notably down-regulating cytochrome P450 3a mediated xenobiotic metabolism. Gut microbiome also modulates the rhythmicity in liver gene expression, likely through microbial metabolites, such as butyrate and propionate that serve as epigenetic modifiers. Additionally, the production of host hormones such as primary bile acids and glucagon like peptide 1 is altered by gut microbiota to modify intermediary metabolism of the host. SUMMARY: Dysregulation of gut microbiota is implicated in various liver diseases such as alcoholic liver disease, non-alcoholic steatohepatitis, liver cirrhosis, cholangitis, and liver cancer. Gut microbiota modifiers such as probiotics and prebiotics are increasingly recognized as novel therapeutic modalities for liver and other types of human diseases.

Indexed as

Bile acidsCholine metabolitesIntestine microbiomeLiver diseasesMicrobial metabolitesShort-chain fatty acids

Identifiers

PMID28983453
PMCPMC5624329
OpenAlexW2592877666

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.